胎盘异常入侵患者的妇产科策略(placenta percreta)

封面


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

怀孕期间最危险的异常情况之一是胎盘的病理性入侵,这会导致孕产妇发病率和死亡率上升。胎盘异常受侵患者在分娩时通常会出现危及生命的子宫出血,尤其是在 placenta percreta 病例中。这往往导致需要进行手术干预——子宫切除术(47.0%-77.8%),一些学者称其为治疗异常胎盘入侵的金标准。其他研究者则倾向于采用保留器官的方法,即完全切除 placenta percreta,切除子宫壁和膀胱上的受损区域,随后进行创面成形术,并恢复邻近器官的完整性。本文介绍了对一例 40 岁女性患者的临床观察,该患者有严重的产科病史,包括胎盘异常受侵(placenta percreta),病理过程不仅涉及子宫前壁,还涉及膀胱。对这种病症的诊断不及时会导致错误的治疗策略,从而引发急性大出血,对女性的健康和生命构成风险。所采取的综合诊断和治疗措施有助于保护盆腔器官和恢复患者的生殖功能。

全文:

INTRODUCTION

The incidence of thyroid diseases (autoimmune thyroiditis and diffuse toxic goiter) tends to increase worldwide [1–4]. Endocrine changes associated with thyroid dysfunction are more common in women than in men [1, 5].

It should be noted that during pregnancy a woman’s body is exposed to increased endocrine organs stress due to hormonal changes and formation of fetoplacental complex [1, 3, 5].

Thyroid hormones such as thyroxine (T4) and triiodothyronine (T3) are pivotal for both intrauterine fetal development and the child’s subsequent extrauterine life [2, 4, 6].

Both low and high levels of thyroid hormones are known to be capable of triggering spontaneous abortion, premature birth, low birth weight, hypoxic and ischemic changes in the brain, etc. [1, 3–6]. Therefore, it is important to continue studying the influence of thyroid function on intrauterine fetal status [2–4].

AIM

The aim of the study was to evaluate the functional status of a fetus in pregnant women with certain thyroid disorders.

MATERIALS AND METHODS

The results of functional fetal assessment were evaluated in 118 pregnant women, who were divided into 3 groups: group 1 (n=44) included patients with autoimmune thyroiditis; group 2 (n=52) patients with diffuse toxic goiter; control group 3 (n=22) patients without physical diseases and gestational complications. Thyroid disease was diagnosed by an endocrinologist during a third trimester consultation based on laboratory and instrumental data. It should be noted that all patients with thyroid diseases first consulted a gynecologist for pregnancy only in the third trimester. Until then, patients with these thyroid disorders had not been followed by an obstetrician/gynecologist or a specialist.

For functional assessment of the fetal status, cardiotocographic curves and ultrasound results obtained at 32–40 weeks of gestation were evaluated.

Cardiotocography (CTG) was performed using a Partecust cardiomonitor (Siemens, Germany) to determine the fetal heart rate, rate variability, fetal movement count, and maximum change in heart rate during movement. CTG data were used for integrated assessment of the fetal status. Computer analysis of CTG was performed using a Fisher score. An International Federation of Gynecology and Obstetrics (FIGO) scale was used for grading.

A fetal biophysical profile was determined using a 6-parameter approach including a non-stress test and ultrasound parameters obtained using an Aloka-1700 system (Hitachi, Japan), such as fetal breathing movements, motor activity and tone, amniotic fluid volume, and placental maturity. Each parameter was scored from 0 to 2.

StatSoft (Russia) was used for statistical processing of the evaluated clinical material. Means and standard deviations were calculated. Student’s t-test was used to determine the reliability of the values between the groups compared.

RESULTS AND DISCUSSION

As shown in Table 1, basal fetal heart rate was not significantly different between groups and averaged 140–147 beats/min. In pregnant women with autoimmune thyroiditis and diffuse toxic goiter, fetal basal heart rate variability was significantly (p <0.05) reduced compared to normal pregnant women.

 

Table 1. Features of fetal cardiotocograms in pregnant women studied (М±m)

Indicator

Group 1 (n=44)

Group 2 (n=52)

Group 3 (n=22)

Basal rhythm (bpm)

145.0±7.0

148.0±2.0

142.0±7.0

Variability (bpm)

6.3±1.4*

7.1±0.8*

11.7±0.9

Accelerations (per 1 hour)

6.6±0.8*

8.2±0.2*

10.4±0.7

Cardiotocogram assessment (points)

6.3±0.4*

7.3±0.1*

8.3±0.4

* Significance (р <0.05) of differences in indicators compared with values in pregnant women from group 3 (control).

 

In addition, the control group had a significantly (p < 0.05) higher acceleration amplitude (10.4±0.7 per hour) than pregnant women with autoimmune thyroiditis and diffuse toxic goiter. It should be noted that in 4 patients with autoimmune thyroiditis (9.1%), fetal cardiotocography patterns had a monotonous basal rhythm.

In general, the mean fetal CTG score was significantly (p <0.05) lower in pregnant women with autoimmune thyroiditis and diffuse toxic goiter compared to controls. This suggests chronic fetal hypoxia in patients with thyroid disease.

The instrumental study of fetal reactivity (mobility) during exercise testing in pregnant women is important for a comprehensive assessment of the adaptive fetal capacity. Non-stress testing records a response of the fetal cardiovascular system in response to fetal movements [7]. A good outcome is defined as a positive reactive test with at least 2 fetal heart rate increases of 15 beats/min lasting at least 15 seconds associated with fetal movements [7].

The studies conducted showed that during pregnancy, patients with thyroid dysfunction were significantly (p < 0.05) less likely to have a reactive positive non-stress test compared to pregnant women in the control group (Table 2).

 

Table 2. Results of non-stress test in pregnant women studied, n (%)

Non-stress test

Group 1 (n=44)

Group 2 (n=52)

Group 3 (n=22)

Reactive

32 (72.2*)

38 (73.1*)

21 (95.5)

Questionable

10 (23.8)

10 (19.2)

1 (9.1)

Areactive

2 (4.0)

4 (7.7)

* Significance (р <0.05) of differences in indicators compared with values in pregnant women from group 3 (control).

 

Table 3 shows results of assessment of fetal biophysical profile in pregnant women from different groups.

 

Table 3. Assessment of the biophysical profile of the fetus in compared groups, n (%)

Indicators

Points

Group 1 (n=44)

Group 2 (n=52)

Group 3 (n=22)

Fetal breathing movements

2

12 (27.3)

29 (57.7)

21 (95.5)

1

10 (22.7)

4 (7.7)

1 (4.5)

0

22 (50.0)

15 (26.9)

Fetal tone

2

19 (45.5)

41 (80.8)

21 (95.5)

1

4 (9.1)

5 (11.5)

1 (4.5)

0

19 (45.5)

4 (7.7)

Fetal motor activity

2

30 (68.2*)

41 (80.8)

21 (95.5)

1

12 (27.3)

10 (19.2)

1 (4.5)

0

2 (4.5)

Stages of placental maturity

2

21 (50.0*)

29 (57.7)

17 (77.3)

1

16 (36.4)

13 (23.1)

4 (18.2)

0

6 (13.6)

9 (19.2)

1 (4.5)

Amniotic fluid

2

24 (54.5)

37 (73.1)

21 (95.5)

1

10 (22.7)

8 (15.4)

1 (4.5)

0

10 (22.7)

5 (11.5)

Non-stress test

2

32 (72.7)

36 (69.2)

19 (86.3)

1

8 (18.2)

6 (23.1)

2 (9.1)

0

4 (9.1)

4 (7.7)

1 (4.5)

* Significance (р <0.05) of differences in indicators compared with values in pregnant women from group 3 (control).

 

A fetal score of 10–12 was observed in only 6 (13.6%) pregnant women with autoimmune thyroiditis, whereas a high score indicating normal fetal condition was 4 times more common in 54.5% of clinical cases in controls.

In patients with diffuse toxic goiter, a fetal biophysical profile with a high score of 10–12 was recorded in 7 (15.9%) cases, which was also significantly less (3.4 times) than in the control group (p <0.05).

In pregnant women with autoimmune thyroiditis and diffuse toxic goiter, 14 (31.8%) and 20 (38.5%) fetuses in groups 1 and 2, respectively, had a satisfactory score. In 10 (45.5%) cases in the control group, such a fetal score was reported according to the biophysical profile.

A controversial fetal biophysical profile was obtained in 18 (40.9%) and 21 (40.4%) pregnant women with autoimmune thyroiditis and diffuse toxic goiter, respectively. In addition, newborns were more likely (90%) to have Apgar scores of 7/7 or 7/8 and various types of postnatal adjustment disorders in the early neonatal period.

An abnormal fetal biophysical profile was reported in 6 (13.6%) pregnant women with autoimmune thyroiditis and in 4 (7.7%) pregnant women with diffuse toxic goiter. In these clinical situations, pregnant women had premature deliveries and neonates were born with moderate asphyxia and required intensive care in the early neonatal period.

It should be noted that changes in CTG parameters and fetal biophysical profile are objective criteria for assessing intrauterine status [7].

Our data confirm the findings of other authors [1–6] that thyroid disease significantly contributes to fetoplacental insufficiency with chronic fetal hypoxia.

In pregnant women with autoimmune thyroiditis and diffuse toxic goiter, changes in respiration, motor function, and muscle tone during fetal instrumental assessment serve as crucial prognostic factors. Non-stress testing is also important in assessing intrauterine fetal status and predicting perinatal outcomes.

CONCLUSION

Our study showed that thyroid dysfunction in pregnant women can negatively affect fetal development. Again, it should be noted that the patients included in this study were not followed by an obstetrician-gynecologist and, for various reasons, did not undergo comprehensive examination until the third trimester. It is possible that early detection of endocrine disorders and timely initiation of treatment to normalize thyroid function may be beneficial to a fetoplacental complex and may prevent chronic fetal hypoxia. This study may serve as a theoretical basis for the development of preventive and therapeutic options to improve perinatal outcomes in pregnant women with thyroid disease.

ADDITIONAL INFO

Authors’ contribution. All authors confirm that their authorship meets the international ICMJE criteria (all authors made a substantial contribution to the conception of the work, acquisition, analysis, interpretation of data for the work, drafting and revising the work, final approval of the version to be published and agree to be accountable for all aspects of the work).

Funding source. The authors declare that there is no external funding for the exploration and analysis work.

Competing interests. The authors declares that there are no obvious and potential conflicts of interest associated with the publication of this article.

Ethical approval. The study was carried out as part of a comprehensive work at the Department of Obstetrics and Gynecology of the Faculty of Medicine of the Astrakhan State Medical University of the Ministry of Health of the Russian Federation and its implementation was agreed upon by the expert commission of this higher educational institution (extract from the protocol dated 07/26/2021 No. 130).

Consent for publication. All patients participating in the study signed the necessary documents on voluntary informed consent to participate in the study and the publication of their medical data.

×

作者简介

Anatoliy I. Ishchenko

I.M. Sechenov First Moscow State Medical University

Email: 7205502@mail.ru
ORCID iD: 0000-0001-5733-953X
SPIN 代码: 3294-3251

MD, Dr. Sci. (Medicine), Professor

俄罗斯联邦, Moscow

Oksana Y. Gorbenko

I.M. Sechenov First Moscow State Medical University

Email: go2601@mail.ru
ORCID iD: 0000-0002-3435-4590
SPIN 代码: 8725-1419

MD, Cand. Sci. (Medicine)

俄罗斯联邦, Moscow

Irina D. Khokhlova

I.M. Sechenov First Moscow State Medical University

编辑信件的主要联系方式.
Email: irhohlova5@gmail.com
ORCID iD: 0000-0001-8547-6750
SPIN 代码: 6858-5235

MD, Cand. Sci. (Medicine), Assistant Professor

俄罗斯联邦, Moscow

Vladimir M. Zuev

I.M. Sechenov First Moscow State Medical University

Email: vlzuev@bk.ru
ORCID iD: 0000-0001-8715-2020
SPIN 代码: 2857-0309

MD, Dr. Sci. (Medicine), Professor

俄罗斯联邦, Moscow

Tea A. Dzhibladze

I.M. Sechenov First Moscow State Medical University

Email: djiba@bk.ru
ORCID iD: 0000-0003-1540-5628
SPIN 代码: 5688-1084

MD, Dr. Sci. (Medicine), Professor

俄罗斯联邦, Moscow

Dmitrii V. Baburin

I.M. Sechenov First Moscow State Medical University

Email: baburin_d_v@staff.sechenov.ru
ORCID iD: 0000-0003-2398-3348
SPIN 代码: 3264-0730
Scopus 作者 ID: 57211347487
Researcher ID: AAQ-3984-2021

MD, Cand. Sci. (Medicine)

俄罗斯联邦, Moscow

参考

  1. Ignatko IV, Davydov AI, Lebedev VA, et al. Placenta accreta spectrum: risk factors, terminology, classification, management strategies. Gynecology, Obstetrics and Perinatology. 2023;22(4):92–101. EDN: RFSBLS doi: 10.20953/1726-1678-2023-4-92-101
  2. Syundyukova EG, Chulanova YuS, Sashenkov SL, et al. Placenta previa and placenta accreta: questions of diagnosing and obstetric management. Russian Bulletin of Obstetrician-Gynecologist. 2022;22(3):12–20. EDN: STIDHQ doi: 10.17116/rosakush20222203112
  3. Jauniaux E, Ayres-de-Campos D, Langhoff-Roos J, et al.; FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel. FIGO classification for the clinical diagnosis of placenta accreta spectrum disorders. Int J Gynaecol Obstet. 2019;146(1):20–24. doi: 10.1002/ijgo.12761
  4. Jauniaux E, Jurkovic D, Hussein AM, Burton GJ. New insights into the etiopathology of placenta accreta spectrum. Am J Obstet Gynecol. 2022;227(3):384–391. doi: 10.1016/j.ajog.2022.02.038
  5. Baranovskaya EI. Etiology and diagnosis of placenta accreta. Russian Bulletin of Obstetrician-Gynecologist. 2020;20(3):24–28. EDN: CGFIOB doi: 10.17116/rosakush20202003124
  6. Wu S, Kocherginsky M, Hibbard JU. Abnormal placentation: twenty-year analysis. Am J Obstet Gynecol. 2005;192(5):1458–1461. doi: 10.1016/j.ajog.2004.12.074
  7. Pan XY, Wang YP, Zheng Z, et al. A marked increase in obstetric hysterectomy for placenta accreta. Chin Med J (Engl). 2015;128(16):2189–2193. doi: 10.4103/0366-6999.162508
  8. Matsuo K, Sangara RN, Matsuzaki S, et al. Placenta previa percreta with surrounding organ involvement: a proposal for management. Int J Gynecol Cancer. 2023;33(10):1633–1644. doi: 10.1136/ijgc-2023-004615
  9. Fonseca A, Ayres de Campos D. Maternal morbidity and mortality due to placenta accreta spectrum disorders. Best Pract Res Clin Obstet Gynaecol. 2021;72:84–91. doi: 10.1016/j.bpobgyn.2020.07.011
  10. Morlando M, Collins S. Placenta accreta spectrum disorders: challenges, risks, and management strategies. Int J Womens Health. 2020;12:1033–1045. doi: 10.2147/IJWH.S224191
  11. Shmakov RG, Pirogova MM, Vasilchenko ON, et al. Conservative surgery in abnormal placenta invasion (5-year experience of V.I. Kulakov National Medical Scientific Centre of Obstetrics, Gynaecology and Perinatal Medicine). Doctor.Ru. 2019;(11):29–34. EDN: UTPKCS doi: 10.31550/1727-2378-2019-166-11-29-34
  12. Davydov AI, Belotserkovtseva LD, Kilicheva II, Voloshchuk IN. Placenta accreta as a cause of postpartum haemorrhage: questions and answers. Gynecology, Obstetrics and Perinatology. 2014;13(3):52–62. EDN SLBTZZ
  13. Vinitsky AA, Shmakov RG, Chuprynin VD. Comparative assessment of the effectiveness of surgical hemostasis methods during organ-preserving delivery in patients with placenta accreta. Obstetrics and Gynecology. 2017;(7):68–74. EDN: ZCQQEV doi: 10.18565/aig.2017.7.68-74
  14. Tskhai VB, Pavlov AV, Garber YuG, et al. Evaluation of the effectiveness of uterine artery embolization in reducing intraoperative blood loss in pregnant women with complete placenta previa. Obstetrics and Gynecology. 2015;(8):59–64. EDN: ULQXVN
  15. Koyama E, Naruse K, Shigetomi H, et al. Combination of B-Lynch brace suture and uterine artery embolization for atonic bleeding after cesarean section in a patient with placenta previa accreta. J. Obstet. Gynaecol. Res. 2012;38(1):345–348. doi: 10.1111/j.1447-0756.2011.01699.x
  16. Jauniaux E, Bhide A. Prenatal ultrasound diagnosis and outcome of placenta previa accreta after cesarean delivery: a systematic review and meta-analysis. Am. J. Obstet. Gynecol. 2017;217(1):27–36. doi: 10.1016/j.ajog.2017.02.050
  17. Horgan R, Abuhamad A. Placenta accreta spectrum: prenatal diagnosis and management. Obstet Gynecol Clin North Am. 2022;49(3):423–438. doi: 10.1016/j.ogc.2022.02.004
  18. Kilcoyne A, Shenoy-Bhangle AS, Roberts DJ, et al. MRI of placenta accreta, placenta increta, and placenta percreta: pearls and pitfalls. Am. J. Roentgenol. 2017;208(1):214–221. doi: 10.2214/AJR.16.16281
  19. Einerson BD, Rodriguez CE, Kennedy AM, et al. Magnetic resonance imaging is often misleading when used as an adjunct to ultrasound in the management of placenta accreta spectrum disorders. Am. J. Obstet. Gynecol. 2018;218(6):618.e1–618.e7. doi: 10.1016/j.ajog.2018.03.013
  20. Dvoretskiy LI, Zaspa EA, Vokalyuk RM. Strategy and tactics of management of patients with iron deficiency anemia. RMJ. 2008;16(7):445–451. (In Russ.) EDN: THXCNF
  21. Matsuzaki S, Ueda Y, Matsuzaki S, et al. Relationship between abnormal placenta and obstetric outcomes: a meta-analysis. Biomedicines. 2023;11(6):1522. doi: 10.3390/biomedicines11061522
  22. Sentilhes L, Seco A, Azria E, et al. Conservative management or cesarean hysterectomy for placenta accreta spectrum: the PACCRETA prospective study. Am J Obstet Gynecol. 2022;226(6):839.e1–839.e24. doi: 10.1016/j.ajog.2021.12.013

补充文件

附件文件
动作
1. JATS XML

版权所有 © Eco-Vector, 2024

Creative Commons License
此作品已接受知识共享署名-非商业性使用-禁止演绎 4.0国际许可协议的许可。

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ:
ПИ № ФС 77 - 86335 от 11.12.2023 г.  
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ:
ЭЛ № ФС 77 - 80633 от 15.03.2021 г.